Ameliorating Gonorrhea: Recent Therapeutic Adaptations and Scope to
Improve its Prevailing Condition

Munyaradzi Amon      Bishi; Palwinder      Kaur; Manish      Vyas; Sandeep      Sharma

doi:10.2174/0118715265258305231124105334

Abstract

Background: Gonorrhea is a sexually transmitted infection (STI) caused by the bacteria Neisseria gonorrhoeae. According to recent research, the prevalence of gonorrhea has been increasing in many parts of the world, with some areas reporting high rates of antibiotic resistance. In the United States, the Centers for Disease Control and Prevention (CDC) reported that the number of reported gonorrhea cases increased by 56% between 2015 and 2019. Globally, the World Health Organization (WHO) estimated that there were 87 million new cases of gonorrhea in 2016, with the highest burden of infection in low- and middle-income countries. Research has also shown that gonorrhea is becoming increasingly resistant to conventional antibiotics, increasing the prevalence of gonorrhea. This raises concerns and challenges in disease management.

Objectives: The present review gives updated insight on the current state of the disease, challenges, and shortcomings of existing approaches along with the modern and alternative direction like vaccine development, its challenges, and scope to confront the existing state of drug resistance and increased rate of incidence. Alternative strategies like immunotherapy and phage therapy along with recent antibiotics researched for the treatment of gonorrhea.

Conclusion: The review provides a thorough insight into the current state of the disease and various available methods used currently and recommended by WHO. To overcome disease prevalence, various alternate therapies are coming into the limelight. However, scientists and researchers show a lack of interest in the drug development and research of gonorrhea, due to less commercial scope, lack of funding, and limited scope in the scientific scenario. These hurdles need to be overcome to meet the WHO vision of reducing gonorrhea by 90% by 2030. So, there is a need to optimize the drug therapy (optimizing dosing schedule, and precision monitoring) to reduce the chance of drug resistance. Also, there is a wide scope for drug and therapeutic system development.

Keywords: Gonorrhea, infectious disease, prevalence, WHO therapy, Gonorrhea Vaccine, Antimicrobial resistance.

Graphical Abstract

[1]
Skerlev M. Čulav-Košćak I. Gonorrhea: New challenges. Clin Dermatol  2014; 32(2): 275-81.
 [http://dx.doi.org/10.1016/j.clindermatol.2013.08.010] [PMID:  24559563]

[2]
Unemo M, Seifert HS, Hook EW, Hawkes S, Ndowa F, Dillon J A R. Gonorrhoea. Nat Rev Dis Primers  2019; 5(1): 79.

[3]
Unemo M, Golparian D, Eyre DW. Antimicrobial resistance in neisseria gonorrhoeae and treatment of gonorrhea. Methods Mol Biol  2019; 1997: 37-58.
 [http://dx.doi.org/10.1007/978-1-4939-9496-0_3] [PMID:  31119616]

[4]
Yang J, Dhital S, Naderer T. Efficacy and safety of injectable and oral antibiotics in treating gonorrhea: A systematic review and network meta-analysis. J Clin Med  2019; 8(12): 2182.
 [http://dx.doi.org/10.3390/jcm8122182] [PMID:  31835724]

[5]
Derbie A, Mekonnen D, Woldeamanuel Y, Abebe T. Azithromycin resistant gonococci: a literature review. Antimicrob Resist Infect Control  2020; 9(1): 138.
 [http://dx.doi.org/10.1186/s13756-020-00805-7] [PMID:  32811545]

[6]
Kirkcaldy RD, Weston E, Segurado AC, Hughes G. Epidemiology of gonorrhoea: A global perspective. Sex Health  2019; 16(5): 401-11.
 [http://dx.doi.org/10.1071/SH19061] [PMID:  31505159]

[7]
Rowley J, Vander Hoorn S, Korenromp E, et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: Global prevalence and incidence estimates, 2016. Bull World Health Organ  2019; 97(8): 548-562P.
 [http://dx.doi.org/10.2471/BLT.18.228486] [PMID:  31384073]

[8]
da Costa-Lourenço APR, Barros Dos Santos KT, Moreira BM, Fracalanzza SEL, Bonelli RR. Antimicrobial resistance in Neisseria gonorrhoeae: History, molecular mechanisms and epidemiological aspects of an emerging global threat. Brazilian J Microbiol  2017; 48: 617-28.

[9]
Whelan J, Abbing-Karahagopian V, Serino L, Unemo M. Gonorrhoea: a systematic review of prevalence reporting globally. BMC Infect Dis  2021; 21(1): 1152.
 [http://dx.doi.org/10.1186/s12879-021-06381-4] [PMID:  34763670]

[10]
Weston EJ, Workowski K, Torrone E, Weinstock H, Stenger MR. Adherence to CDC Recommendations for the Treatment of Uncomplicated Gonorrhea — STD Surveillance Network, United States, 2016. MMWR Morb Mortal Wkly Rep  2018; 67(16): 473-6.
 [http://dx.doi.org/10.15585/mmwr.mm6716a4] [PMID:  29698384]

[11]
Zheng Y, Yu Q, Lin Y, et al. Global burden and trends of sexually transmitted infections from 1990 to 2019: an observational trend study. Lancet Infect Dis  2022; 22(4): 541-51.
 [http://dx.doi.org/10.1016/S1473-3099(21)00448-5] [PMID:  34942091]

[12]
Peters RPH, Chico RM, Rowley J, Low N. Estimating the global burden of sexually transmitted infections. Lancet Infect Dis  2022; 22(8): 1112-3.
 [http://dx.doi.org/10.1016/S1473-3099(22)00415-7] [PMID:  35870456]

[13]
Chesson HW, Mayaud P, Aral SO. Sexually transmitted infections: Impact and cost-effectiveness of prevention. Washington, DC: The International Bank for Reconstruction and Development 2017.

[14]
Sharma M, Rewari BB, Aditama TY, Turlapati P, Dallabetta G, Steen R. Control of sexually transmitted infections and global elimination targets, South-East Asia Region. Bull World Health Organ  2021; 99(4): 304-11.
 [http://dx.doi.org/10.2471/BLT.20.254003] [PMID:  33953448]

[15]
Vicentini CB, Manfredini S, Maritati M, Di Nuzzo M, Contini C. Gonorrhea, a current disease with ancient roots: From the remedies of the past to future perspectives. Infez Med  2019; 27(2): 212-21.
 [PMID:  31205048]

[16]
Martí-Pastor M, García de Olalla P, Barberá MJ, et al. Epidemiology of infections by HIV, Syphilis, Gonorrhea and Lymphogranuloma Venereum in Barcelona City: A population-based incidence study. BMC Public Health  2015; 15(1): 1015.
 [http://dx.doi.org/10.1186/s12889-015-2344-7] [PMID:  26438040]

[17]
Pollock ED, Clay PA, Kreisel KM, Spicknall IH. Estimated incidence and prevalence of gonorrhea in the United States, 2006-2019. Sex Transm Dis  2023; 50(4): 188-95.
 [http://dx.doi.org/10.1097/OLQ.0000000000001763] [PMID:  36598837]

[18]
Kreisel KM, Weston EJ, St Cyr SB, Spicknall IH. Estimates of the Prevalence and Incidence of Chlamydia and Gonorrhea Among US Men and Women, 2018. Sex Transm Dis  2021; 48(4): 222-31.
 [http://dx.doi.org/10.1097/OLQ.0000000000001382] [PMID:  33492094]

[19]
Fairley CK, Hocking JS, Zhang L, Chow EPF. Frequent transmission of gonorrhea in men who have sex with men. Emerg Infect Dis  2017; 23(1): 102-4.
 [http://dx.doi.org/10.3201/eid2301.161205] [PMID:  27983487]

[20]
Ribeiro S, de Sousa D, Medina D, Castro R, Lopes Â, Rocha M. Prevalence of gonorrhea and chlamydia in a community clinic for men who have sex with men in Lisbon, Portugal. Int J STD AIDS  2019; 30(10): 951-9.
 [http://dx.doi.org/10.1177/0956462419855484] [PMID:  31284840]

[21]
Chow EPF, Camilleri S, Ward C, et al. Duration of gonorrhoea and chlamydia infection at the pharynx and rectum among men who have sex with men: a systematic review. Sex Health  2016; 13(3): 199-204.
 [http://dx.doi.org/10.1071/SH15175] [PMID:  26886136]

[22]
Lutz AR. Screening for asymptomatic extragenital gonorrhea and chlamydia in men who have sex with men: Significance, recommendations, and options for overcoming barriers to testing. LGBT Health  2015; 2(1): 27-34.
 [http://dx.doi.org/10.1089/lgbt.2014.0056] [PMID:  26790015]

[23]
Lenz JD, Dillard JP. Pathogenesis of Neisseria gonorrhoeae and the Host Defense in Ascending Infections of Human Fallopian Tube. Front Immunol  2018; 9: 2710.
 [http://dx.doi.org/10.3389/fimmu.2018.02710] [PMID:  30524442]

[24]
Château A, Seifert HS. Neisseria gonorrhoeae survives within and modulates apoptosis and inflammatory cytokine production of human macrophages. Cell Microbiol  2016; 18(4): 546-60.
 [http://dx.doi.org/10.1111/cmi.12529] [PMID:  26426083]

[25]
Quillin SJ, Seifert HS. Neisseria gonorrhoeae host adaptation and pathogenesis. Nat Rev Microbiol  2018; 16(4): 226-40.
 [http://dx.doi.org/10.1038/nrmicro.2017.169] [PMID:  29430011]

[26]
Whiley DM, Lahra MM, Unemo M. Prospects of untreatable gonorrhea and ways forward. Future Microbiol  2015; 10(3): 313-6.
 [http://dx.doi.org/10.2217/fmb.14.138] [PMID:  25812453]

[27]
Suay-García B, Pérez-Gracia MT. Neisseria gonorrhoeae Infections. Pathogens  2020; 9(8): 647.
 [http://dx.doi.org/10.3390/pathogens9080647] [PMID:  32806522]

[28]
Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev  2014; 27(3): 587-613.
 [http://dx.doi.org/10.1128/CMR.00010-14] [PMID:  24982323]

[29]
Unemo M. Current and future antimicrobial treatment of gonorrhoea – the rapidly evolving Neisseria gonorrhoeae continues to challenge. BMC Infect Dis  2015; 15(1): 364.
 [http://dx.doi.org/10.1186/s12879-015-1029-2] [PMID:  26293005]

[30]
Cyr SS, Barbee L, Workowski KA, Bachmann LH, Pham C, Schlanger K. CDC STI Gonorrhea treatment guidelines. Morb Mortal Wkly Rep Updat  2020; 69: 1911-6.

[31]
Mathew R, Chahin M, Isache C. Neisseria gonorrhoeae: An Unexpected Cause of Polyarthritis and Meningitis. J Investig Med High Impact Case Rep  2021; 9.
 [http://dx.doi.org/10.1177/23247096211012194] [PMID:  33928799]

[32]
Creighton S. Gonorrhoea. BMJ Clin Evid 2014.

[33]
WHO WHO guidelines for the treatment of Neisseria gonorrhoeae.  2016. Available from https://www.who.int/publications/i/item/9789241549691

[34]
Toledano Medina MÁ, Merinas-Amo T, Fernández-Bedmar Z, et al. Physicochemical characterization and biological activities of black and white garlic: In vivo and in vitro assays. Foods  2019; 8.

[35]
Silva O, Caldeira G, Serrano R. A review of the role of medicinal plants on Neisseria gonorrhoeae infection. Eur J Integr Med  2020; 39: 101211.
 [http://dx.doi.org/10.1016/j.eujim.2020.101211]

[36]
Mahira A, Mahbuba Nabi V. In infectious diseases, Echinacea comes to the rescue Ann. Syst Biol  2022; 5: 8-9.

[37]
Shokeen P, Bala M, Tandon V. Evaluation of the activity of 16 medicinal plants against Neisseria gonorrhoeae. Int J Antimicrob Agents  2009; 33(1): 86-91.
 [http://dx.doi.org/10.1016/j.ijantimicag.2008.07.022] [PMID:  18819776]

[38]
Mollik AH, Islam T, Khatun A, et al. Medicinal plants used against syphilis and gonorrhea by traditional medicinal practitioners of Bangladesh. Planta Med  2009; 75(9): PH40.
 [http://dx.doi.org/10.1055/s-0029-1234757]

[39]
Khoshkharam M, Shahrajabian MH, Singh RB, et al. Sumac: A functional food and herbal remedy in traditional herbal medicine in the Asia. In: Singh RB, Watanabe S, Isaza AA, Eds. Functional Foods and Nutraceuticals in Metabolic and Non-Communicable Diseases.  Academic Press 2022; pp. 261-6.

[40]
Acharya GS. Clinical indications of avipattikara choorna an experiential and scientific view. Int Res J Ayurveda Yoga  2022; 05: 83-5.

[41]
Prasathkumar M, Anisha S, Dhrisya C, Becky R, Sadhasivam S. Therapeutic and pharmacological efficacy of selective Indian medicinal plants – A review. Phytomedicine Plus  2021; 1: 100029.

[42]
Ranjbar R, Bagheri H, Ghasemi F, Guest PC, Sahebkar A. Effects of Curcumin and Its Analogues on Infectious Diseases Studies on Biomarkers and New Targets in Aging Research in Iran: Focus on Turmeric and Curcumin.  Cham: Springer 2021; pp. 75-101.

[43]
Judson FN. Treatment of uncomplicated gonorrhea with ceftriaxone: a review. Sex Transm Dis  1986; 13(3): 199-202.
 [http://dx.doi.org/10.1097/00007435-198607000-00021] [PMID:  3094173]

[44]
Balduck M, Laumen JGE, Abdellati S, et al. Tolerance to Ceftriaxone in Neisseria gonorrhoeae: Rapid Induction in WHO P Reference Strain and Detection in Clinical Isolates.  Basel, Switzerland: Antibiot 2022; p. 11.

[45]
Kuehn BM. Updated recommendations for gonorrhea treatment. JAMA  2021; 325(6): 523.
 [PMID:  33560331]

[46]
Fan W, Zhang Q. Risk factors for male patients with gonorrhoea complicated by inflammation of the paraurethral glands around the external urethral orifice. Int J STD AIDS  2012; 23: 400-2.

[47]
Lewis DA. New treatment options for Neisseria gonorrhoeae in the era of emerging antimicrobial resistance. Sex Health  2019; 16(5): 449-56.
 [http://dx.doi.org/10.1071/SH19034] [PMID:  31292063]

[48]
Lancaster JW, Mahoney MV, Mandal S, Lawrence KR. Update on treatment options for gonococcal infections. Pharmacotherapy  2015; 35(9): 856-68.
 [http://dx.doi.org/10.1002/phar.1627] [PMID:  26343813]

[49]
Anon . Update to CDC’s sexually transmitted diseases treatment guidelines, 2010: Oral cephalosporins no longer a recommended treatment for gonococcal infections. JAMA  2012; 308: 1850-3.
 [http://dx.doi.org/10.1001/2012.jama.11292]

[50]
Pleininger S, Indra A, Golparian D, et al. Extensively drug-resistant (XDR) Neisseria gonorrhoeae causing possible gonorrhoea treatment failure with ceftriaxone plus azithromycin in Austria, April 2022. Euro Surveill  2022; 27(24): 1-5.
 [http://dx.doi.org/10.2807/1560-7917.ES.2022.27.24.2200455] [PMID:  35713023]

[51]
Ison CA, Hussey J, Sankar KN, Evans J, Alexander S. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill  2011; 16(14): 1-4.
 [http://dx.doi.org/10.2807/ese.16.14.19833-en] [PMID:  21492528]

[52]
Butler MM, Waidyarachchi SL, Connolly KL, et al. Aminomethyl spectinomycins as therapeutics for drug-resistant gonorrhea and chlamydia coinfections. Antimicrob Agents Chemother  2018; 62(5): e00325-18.
 [http://dx.doi.org/10.1128/AAC.00325-18] [PMID:  29483122]

[53]
Unemo M, Jensen JS. Antimicrobial-resistant sexually transmitted infections: Gonorrhoea and Mycoplasma genitalium. Nat Rev Urol  2017; 14(3): 139-52.
 [http://dx.doi.org/10.1038/nrurol.2016.268] [PMID:  28072403]

[54]
Lewis DA. Global resistance of Neisseria gonorrhoeae. Curr Opin Infect Dis  2014; 27(1): 62-7.
 [http://dx.doi.org/10.1097/QCO.0000000000000025] [PMID:  24275696]

[55]
Fernandes P, Craft JC. Phase 3 trial of treating gonorrhoea with solithromycin. Lancet Infect Dis  2019; 19(9): 928.
 [http://dx.doi.org/10.1016/S1473-3099(19)30430-X] [PMID:  31478511]

[56]
Chen MY, McNulty A, Avery A, et al. Solithromycin versus ceftriaxone plus azithromycin for the treatment of uncomplicated genital gonorrhoea (SOLITAIRE-U): A randomised phase 3 non-inferiority trial. Lancet Infect Dis  2019; 19(8): 833-42.
 [http://dx.doi.org/10.1016/S1473-3099(19)30116-1] [PMID:  31196813]

[57]
Chung PY. Current technology in the discovery and development of novel antibacterials. Curr Drug Targets  2018; 19(7): 832-40.
 [http://dx.doi.org/10.2174/1389450118666170911114604] [PMID:  28891454]

[58]
Penchovsky R, Traykovska M. Designing drugs that overcome antibacterial resistance: Where do we stand and what should we do? Expert Opin Drug Discov  2015; 10(6): 631-50.
 [http://dx.doi.org/10.1517/17460441.2015.1048219] [PMID:  25981754]

[59]
Suay-García B, Pérez-Gracia M. Future prospects for neisseria gonorrhoeae treatment. Antibiotics  2018; 7(2): 49.
 [http://dx.doi.org/10.3390/antibiotics7020049] [PMID:  29914071]

[60]
Rice PA, Shafer WM, Ram S, Jerse AE. Neisseria gonorrhoeae: Drug resistance, mouse models, and vaccine development. Annu Rev Microbiol  2017; 71(1): 665-86.
 [http://dx.doi.org/10.1146/annurev-micro-090816-093530] [PMID:  28886683]

[61]
Russell MW, Jerse AE, Gray-Owen SD. Progress toward a gonococcal vaccine: The way forward. Front Immunol  2019; 10: 2417.
 [http://dx.doi.org/10.3389/fimmu.2019.02417] [PMID:  31681305]

[62]
Spellberg B, Guidos R, Gilbert D, et al. The epidemic of antibiotic-resistant infections: A call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis  2008; 46(2): 155-64.
 [http://dx.doi.org/10.1086/524891] [PMID:  18171244]

[63]
Renwick MJ, Brogan DM, Mossialos E. A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics. J Antibiot  2016; 69(2): 73-88.
 [http://dx.doi.org/10.1038/ja.2015.98] [PMID:  26464014]

[64]
Cook MA, Wright GD. The past, present, and future of antibiotics. Sci Transl Med  2022; 14(657): eabo7793.
 [http://dx.doi.org/10.1126/scitranslmed.abo7793] [PMID:  35947678]

[65]
Mancuso AM, Gandhi MA, Slish J. Solithromycin (CEM-101): A New Fluoroketolide Antibiotic and Its Role in the Treatment of Gonorrhea. J Pharm Pract  2018; 31(2): 195-201.
 [http://dx.doi.org/10.1177/0897190017708073] [PMID:  28490220]

[66]
de Vries HJC, Schim-van der Loeff MF. Solithromycin for the treatment of drug-resistant gonorrhoea. Lancet Infect Dis  2019; 19(8): 791-2.
 [http://dx.doi.org/10.1016/S1473-3099(19)30115-X] [PMID:  31196808]

[67]
Taylor SN, Morris DH, Avery AK, et al. Gepotidacin for the treatment of uncomplicated urogenital gonorrhea: A phase 2, randomized, dose-ranging, single-oral dose evaluation. Clin Infect Dis  2018; 67(4): 504-12.
 [http://dx.doi.org/10.1093/cid/ciy145] [PMID:  29617982]

[68]
Aitolo GL, Adeyemi OS, Afolabi BL, Owolabi AO. Neisseria gonorrhoeae antimicrobial resistance: Past to present to future. Curr Microbiol  2021; 78(3): 867-78.
 [http://dx.doi.org/10.1007/s00284-021-02353-8] [PMID:  33528603]

[69]
Taylor SN, Marrazzo J, Batteiger BE, et al. Single-Dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea. N Engl J Med  2018; 379(19): 1835-45.
 [http://dx.doi.org/10.1056/NEJMoa1706988] [PMID:  30403954]

[70]
Veve MP, Wagner JL. Lefamulin: Review of a promising novel pleuromutilin antibiotic. Pharmacotherapy  2018; 38(9): 935-46.
 [http://dx.doi.org/10.1002/phar.2166] [PMID:  30019769]

[71]
Humphries R, Bobenchik AM, Hindler JA, Schuetz AN. Overview of changes to the clinical and laboratory standards institute performance standards for antimicrobial susceptibility testing, M100. J Clin Microbiol  2021; 59: e0021321.

[72]
Jacobsson S, Golparian D, Oxelbark J, et al. Pharmacodynamic evaluation of lefamulin in the treatment of gonorrhea using a hollow fiber infection model simulating Neisseria gonorrhoeae infections. Front Pharmacol  2022; 13: 1035841.
 [http://dx.doi.org/10.3389/fphar.2022.1035841] [PMID:  36452226]

[73]
Baker SJ, Payne DJ, Rappuoli R, De Gregorio E. Technologies to address antimicrobial resistance. Proc Natl Acad Sci  2018; 115(51): 12887-95.
 [http://dx.doi.org/10.1073/pnas.1717160115] [PMID:  30559181]

[74]
Leung E, Weil DE, Raviglione M, Nakatani H. The WHO policy package to combat antimicrobial resistance. Bull World Health Organ  2011; 89(5): 390-2.
 [http://dx.doi.org/10.2471/BLT.11.088435] [PMID:  21556308]

[75]
Cater K. Międzybrodzki R, Morozova V, et al Potential for Phages in the Treatment of Bacterial Sexually Transmitted Infections.  Basel, Switzerland: Antibiot 2021; p. 10.

[76]
Gottlieb SL, Johnston C. Future prospects for new vaccines against sexually transmitted infections. Curr Opin Infect Dis  2017; 30(1): 77-86.
 [http://dx.doi.org/10.1097/QCO.0000000000000343] [PMID:  27922851]

[77]
Gala R, Zaman R, D’Souza M, Zughaier S. Novel whole-cell inactivated neisseria gonorrhoeae microparticles as vaccine formulation in microneedle-based transdermal immunization. Vaccines  2018; 6(3): 60.
 [http://dx.doi.org/10.3390/vaccines6030060] [PMID:  30181504]

[78]
Gottlieb SL, Jerse AE, Delany-Moretlwe S, Deal C, Giersing BK. Advancing vaccine development for gonorrhoea and the Global STI Vaccine Roadmap. Sex Health  2019; 16(5): 426-32.
 [http://dx.doi.org/10.1071/SH19060] [PMID:  31476278]

[79]
Edwards JL, Jennings MP, Apicella MA, Seib KL. Is gonococcal disease preventable? The importance of understanding immunity and pathogenesis in vaccine development. Crit Rev Microbiol  2016; 42(6): 928-41.
 [http://dx.doi.org/10.3109/1040841X.2015.1105782] [PMID:  26805040]

[80]
Thakur SD, Levett PN, Horsman GB, Dillon JAR. Molecular epidemiology of Neisseria gonorrhoeae isolates from Saskatchewan, Canada: Utility of NG-MAST in predicting antimicrobial susceptibility regionally. Sex Transm Infect  2014; 90(4): 297-302.
 [http://dx.doi.org/10.1136/sextrans-2013-051229] [PMID:  24503900]

[81]
Rodrigues MQ, Alves PM, Roldão A. Functionalizing Ferritin Nanoparticles for Vaccine Development. Pharmaceutics  2021; 13(10): 1621.
 [http://dx.doi.org/10.3390/pharmaceutics13101621] [PMID:  34683914]

[82]
Ladner JT, Grubaugh ND, Pybus OG, Andersen KG. Precision epidemiology for infectious disease control. Nat Med  2019; 25(2): 206-11.
 [http://dx.doi.org/10.1038/s41591-019-0345-2] [PMID:  30728537]

Rights & Permissions Print Cite

Article Metrics

14

1

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/0118715265258305231124105334	Print ISSN 1871-5265
Publisher Name Bentham Science Publisher	Online ISSN 2212-3989

Infectious Disorders - Drug Targets

Ameliorating Gonorrhea: Recent Therapeutic Adaptations and Scope to Improve its Prevailing Condition

Abstract

Graphical Abstract

Related Journals

Related Books